

# Article - Billing and Coding: Lab: Controlled Substance Monitoring and Drugs of Abuse Testing (A55030)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

## Contractor Information

| CONTRACTOR NAME                                    | CONTRACT TYPE | CONTRACT NUMBER | JURISDICTION | STATES       |
|--|---------------|-----------------|--------------|--------------|
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 02101 - MAC A   | J - F        | Alaska       |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 02102 - MAC B   | J - F        | Alaska       |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 02201 - MAC A   | J - F        | Idaho        |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 02202 - MAC B   | J - F        | Idaho        |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 02301 - MAC A   | J - F        | Oregon       |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 02302 - MAC B   | J - F        | Oregon       |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 02401 - MAC A   | J - F        | Washington   |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 02402 - MAC B   | J - F        | Washington   |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 03101 - MAC A   | J - F        | Arizona      |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 03102 - MAC B   | J - F        | Arizona      |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 03201 - MAC A   | J - F        | Montana      |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 03202 - MAC B   | J - F        | Montana      |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 03301 - MAC A   | J - F        | North Dakota |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 03302 - MAC B   | J - F        | North Dakota |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 03401 - MAC A   | J - F        | South Dakota |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 03402 - MAC B   | J - F        | South Dakota |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 03501 - MAC A   | J - F        | Utah         |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 03502 - MAC B   | J - F        | Utah         |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 03601 - MAC A   | J - F        | Wyoming      |
| <a href="#">Noridian Healthcare Solutions, LLC</a> | A and B MAC   | 03602 - MAC B   | J - F        | Wyoming      |

## Article Information

### General Information

**Article ID**  
A55030

**Article Title**

**AMA CPT / ADA CDT / AHA NUBC Copyright Statement**

CPT codes, descriptions and other data only are copyright 2022 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Billing and Coding: Lab: Controlled Substance Monitoring and Drugs of Abuse Testing

## Article Type

Billing and Coding

## Original Effective Date

06/28/2016

## Revision Effective Date

07/01/2023

## Revision Ending Date

N/A

## Retirement Date

N/A

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2022 American Dental Association. All rights reserved.

Copyright © 2023, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312 893 6816.

Making copies or utilizing the content of the UB04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB04 Manual and/or codes and descriptions; and/or making any commercial use of UB04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

## CMS National Coverage Policy

Title XVIII of the Social Security Act, §1833(e) prohibits Medicare payment for any claim lacking the necessary documentation to process the claim.

CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 15, §80.1.2 - A/B MAC (B) Contacts with Independent Clinical Laboratories

## Article Guidance

### Article Text

The information in this article contains billing, coding, and other guidelines that complement the Local Coverage Determination (LCD) for Lab: Controlled Substance Monitoring and Drugs of Abuse Testing L36707.

Effective January 1, 2017, controlled substance testing providers should apply the following coding and billing guidelines for L36707 - Lab: Controlled Substance Monitoring and Drugs of Abuse Testing.

- To receive reimbursement for controlled substance and drugs of abuse testing, the service reported on the claim MUST match the service ordered by the physician.
- Incidental findings not ordered by the physician are not a covered service and will be denied.
- A maximum of one presumptive urine drug test may be submitted and paid per patient DOS.
- A maximum of one definitive urine drug test may be submitted and paid per patient DOS.

Reminder - DOS refers to the date of the sample collection, not the date the test was run.

### **Presumptive Urine Drug Testing (UDT)**

Providers may ONLY perform and report one of the following three types of presumptive UDT available per patient DOS:

1. **80305**: Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (e.g. immunoassay) capable of being read by direct optical observation only (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service.
2. **80306**: Drug test(s), presumptive, any number of drug classes, qualitative, any number of devices or procedures, (e.g., immunoassay) read by instrument assisted direct optical observation (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service.
3. **80307**: Drug test(s), presumptive, any number of drug classes, qualitative, any number of devices or procedures by instrument chemistry analyzers (e.g., utilizing immunoassay [e.g., EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (e.g., GC, HPLC), and mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service.

### **Definitive (Qualitative or Quantitative) UDT Testing**

Based on the number of drug classes indicated for the patient's needs, providers may ONLY perform and report one of the following five UDT services per patient DOS:

1. **G0480**: Drug test(s) definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day, 1-7 drug class(es), including metabolite(s) if performed.
2. **G0481**: Drug test(s) definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day, 8-14 drug class(es), including metabolites(s) if performed.
3. **G0482**: Drug test(s) definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day, 15-21 drug classes, including metabolites(s) if performed.
4. **G0483**: Drug test(s) definitive, utilizing (1) drug identification methods able to identify individual drugs and

distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day, 22 or more drug classes, including metabolites(s) if performed.

5. **G0659**: Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem), excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes.

### **Coding/Billing Clarification of Non-Covered Services**

- Reflex testing for IA presumptive positives may only be performed by laboratories other than physician office labs (POL). Physicians in POL are expected to determine the medical necessity for definitive testing for a presumptive positive result and document the necessity in the medical record because they have specific patient information and may not need definitive testing.
- When a presumptive test is negative for a patient on a prescribed medication, a definitive drug test may be performed.
- Only one presumptive service may be billed per patient, per DOS, regardless of the provider.
- Medicare will process the first presumptive service received per patient, per DOS. All subsequent claims for a presumptive service for the same patient and same DOS will be denied.
- Only one definitive service may be billed per patient, per DOS, regardless of the provider.
- Medicare will process the first definitive service received per patient, per DOS. All subsequent claims for a definitive service for the same patient and same DOS will be denied.

To report a Controlled Substance Monitoring and Drugs of Abuse Testing service, please submit the following claim information:

- Select the appropriate CPT® code
- Enter 1 unit of service (UOS)
- Select the appropriate ICD-10-CM code

---

## **Coding Information**

### **CPT/HCPCS Codes**

#### **Group 1 Paragraph:**

The following codes are new and effective 01/01/2017: G0659, 80305, 80306 and 80307.

#### **Group 1 Codes: (9 Codes)**

| CODE  | DESCRIPTION   |
|-------|---|
| 80305 | DRUG TEST(S), PRESUMPTIVE, ANY NUMBER OF DRUG CLASSES, ANY NUMBER OF DEVICES OR PROCEDURES; CAPABLE OF BEING READ BY DIRECT OPTICAL OBSERVATION ONLY (EG, UTILIZING IMMUNOASSAY [EG, DIPSTICKS, CUPS, CARDS, OR CARTRIDGES]), INCLUDES SAMPLE VALIDATION WHEN PERFORMED, PER DATE OF SERVICE  |
| 80306 | DRUG TEST(S), PRESUMPTIVE, ANY NUMBER OF DRUG CLASSES, ANY NUMBER OF DEVICES OR PROCEDURES; READ BY INSTRUMENT ASSISTED DIRECT OPTICAL OBSERVATION (EG, UTILIZING IMMUNOASSAY [EG, DIPSTICKS, CUPS, CARDS, OR CARTRIDGES]), INCLUDES SAMPLE VALIDATION WHEN PERFORMED, PER DATE OF SERVICE  |
| 80307 | DRUG TEST(S), PRESUMPTIVE, ANY NUMBER OF DRUG CLASSES, ANY NUMBER OF DEVICES OR PROCEDURES; BY INSTRUMENT CHEMISTRY ANALYZERS (EG, UTILIZING IMMUNOASSAY [EG, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), CHROMATOGRAPHY (EG, GC, HPLC), AND MASS SPECTROMETRY EITHER WITH OR WITHOUT CHROMATOGRAPHY, (EG, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) INCLUDES SAMPLE VALIDATION WHEN PERFORMED, PER DATE OF SERVICE  |
| G0480 | DRUG TEST(S), DEFINITIVE, UTILIZING (1) DRUG IDENTIFICATION METHODS ABLE TO IDENTIFY INDIVIDUAL DRUGS AND DISTINGUISH BETWEEN STRUCTURAL ISOMERS (BUT NOT NECESSARILY STEREOISOMERS), INCLUDING, BUT NOT LIMITED TO GC/MS (ANY TYPE, SINGLE OR TANDEM) AND LC/MS (ANY TYPE, SINGLE OR TANDEM AND EXCLUDING IMMUNOASSAYS (E.G., IA, EIA, ELISA, EMIT, FPIA) AND ENZYMATIC METHODS (E.G., ALCOHOL DEHYDROGENASE)), (2) STABLE ISOTOPE OR OTHER UNIVERSALLY RECOGNIZED INTERNAL STANDARDS IN ALL SAMPLES (E.G., TO CONTROL FOR MATRIX EFFECTS, INTERFERENCES AND VARIATIONS IN SIGNAL STRENGTH), AND (3) METHOD OR DRUG-SPECIFIC CALIBRATION AND MATRIX-MATCHED QUALITY CONTROL MATERIAL (E.G., TO CONTROL FOR INSTRUMENT VARIATIONS AND MASS SPECTRAL DRIFT); QUALITATIVE OR QUANTITATIVE, ALL SOURCES, INCLUDES SPECIMEN VALIDITY TESTING, PER DAY; 1-7 DRUG CLASS(ES), INCLUDING METABOLITE(S) IF PERFORMED |
| G0481 | DRUG TEST(S), DEFINITIVE, UTILIZING (1) DRUG IDENTIFICATION METHODS ABLE TO IDENTIFY INDIVIDUAL DRUGS AND DISTINGUISH BETWEEN STRUCTURAL ISOMERS (BUT NOT NECESSARILY STEREOISOMERS), INCLUDING, BUT NOT LIMITED TO GC/MS (ANY TYPE, SINGLE OR TANDEM) AND LC/MS (ANY TYPE, SINGLE OR TANDEM AND EXCLUDING IMMUNOASSAYS (E.G., IA, EIA, ELISA, EMIT, FPIA) AND ENZYMATIC METHODS (E.G., ALCOHOL DEHYDROGENASE)), (2) STABLE ISOTOPE OR OTHER UNIVERSALLY RECOGNIZED INTERNAL STANDARDS IN ALL SAMPLES (E.G., TO CONTROL FOR MATRIX EFFECTS, INTERFERENCES AND VARIATIONS IN SIGNAL STRENGTH), AND (3) METHOD OR DRUG-SPECIFIC CALIBRATION AND MATRIX-MATCHED QUALITY CONTROL MATERIAL (E.G., TO CONTROL FOR INSTRUMENT VARIATIONS AND MASS SPECTRAL DRIFT); QUALITATIVE OR QUANTITATIVE, ALL SOURCES, INCLUDES SPECIMEN VALIDITY  |

| CODE  | DESCRIPTION  |
|-------|--|
|       | TESTING, PER DAY; 8-14 DRUG CLASS(ES), INCLUDING METABOLITE(S) IF PERFORMED  |
| G0482 | DRUG TEST(S), DEFINITIVE, UTILIZING (1) DRUG IDENTIFICATION METHODS ABLE TO IDENTIFY INDIVIDUAL DRUGS AND DISTINGUISH BETWEEN STRUCTURAL ISOMERS (BUT NOT NECESSARILY STEREOISOMERS), INCLUDING, BUT NOT LIMITED TO GC/MS (ANY TYPE, SINGLE OR TANDEM) AND LC/MS (ANY TYPE, SINGLE OR TANDEM AND EXCLUDING IMMUNOASSAYS (E.G., IA, EIA, ELISA, EMIT, FPIA) AND ENZYMATIC METHODS (E.G., ALCOHOL DEHYDROGENASE)), (2) STABLE ISOTOPE OR OTHER UNIVERSALLY RECOGNIZED INTERNAL STANDARDS IN ALL SAMPLES (E.G., TO CONTROL FOR MATRIX EFFECTS, INTERFERENCES AND VARIATIONS IN SIGNAL STRENGTH), AND (3) METHOD OR DRUG-SPECIFIC CALIBRATION AND MATRIX-MATCHED QUALITY CONTROL MATERIAL (E.G., TO CONTROL FOR INSTRUMENT VARIATIONS AND MASS SPECTRAL DRIFT); QUALITATIVE OR QUANTITATIVE, ALL SOURCES, INCLUDES SPECIMEN VALIDITY TESTING, PER DAY; 15-21 DRUG CLASS(ES), INCLUDING METABOLITE(S) IF PERFORMED      |
| G0483 | DRUG TEST(S), DEFINITIVE, UTILIZING (1) DRUG IDENTIFICATION METHODS ABLE TO IDENTIFY INDIVIDUAL DRUGS AND DISTINGUISH BETWEEN STRUCTURAL ISOMERS (BUT NOT NECESSARILY STEREOISOMERS), INCLUDING, BUT NOT LIMITED TO GC/MS (ANY TYPE, SINGLE OR TANDEM) AND LC/MS (ANY TYPE, SINGLE OR TANDEM AND EXCLUDING IMMUNOASSAYS (E.G., IA, EIA, ELISA, EMIT, FPIA) AND ENZYMATIC METHODS (E.G., ALCOHOL DEHYDROGENASE)), (2) STABLE ISOTOPE OR OTHER UNIVERSALLY RECOGNIZED INTERNAL STANDARDS IN ALL SAMPLES (E.G., TO CONTROL FOR MATRIX EFFECTS, INTERFERENCES AND VARIATIONS IN SIGNAL STRENGTH), AND (3) METHOD OR DRUG-SPECIFIC CALIBRATION AND MATRIX-MATCHED QUALITY CONTROL MATERIAL (E.G., TO CONTROL FOR INSTRUMENT VARIATIONS AND MASS SPECTRAL DRIFT); QUALITATIVE OR QUANTITATIVE, ALL SOURCES, INCLUDES SPECIMEN VALIDITY TESTING, PER DAY; 22 OR MORE DRUG CLASS(ES), INCLUDING METABOLITE(S) IF PERFORMED |
| G0659 | DRUG TEST(S), DEFINITIVE, UTILIZING DRUG IDENTIFICATION METHODS ABLE TO IDENTIFY INDIVIDUAL DRUGS AND DISTINGUISH BETWEEN STRUCTURAL ISOMERS (BUT NOT NECESSARILY STEREOISOMERS), INCLUDING BUT NOT LIMITED TO GC/MS (ANY TYPE, SINGLE OR TANDEM) AND LC/MS (ANY TYPE, SINGLE OR TANDEM), EXCLUDING IMMUNOASSAYS (E.G., IA, EIA, ELISA, EMIT, FPIA) AND ENZYMATIC METHODS (E.G., ALCOHOL DEHYDROGENASE), PERFORMED WITHOUT METHOD OR DRUG-SPECIFIC CALIBRATION, WITHOUT MATRIX-MATCHED QUALITY CONTROL MATERIAL, OR WITHOUT USE OF STABLE ISOTOPE OR OTHER UNIVERSALLY RECOGNIZED INTERNAL STANDARD(S) FOR EACH DRUG, DRUG METABOLITE OR DRUG CLASS PER SPECIMEN; QUALITATIVE OR QUANTITATIVE, ALL SOURCES, INCLUDES SPECIMEN VALIDITY TESTING, PER DAY, ANY NUMBER OF DRUG CLASSES  |
| 0227U | DRUG ASSAY, PRESUMPTIVE, 30 OR MORE DRUGS OR METABOLITES, URINE,   |

| CODE | DESCRIPTION  |
|------|--|
|      | LIQUID CHROMATOGRAPHY WITH TANDEM MASS SPECTROMETRY (LC-MS/MS) USING MULTIPLE REACTION MONITORING (MRM), WITH DRUG OR METABOLITE DESCRIPTION, INCLUDES SAMPLE VALIDATION |

### CPT/HCPCS Modifiers

#### Group 1 Paragraph:

N/A

#### Group 1 Codes:

N/A

### ICD-10-CM Codes that Support Medical Necessity

#### Group 1 Paragraph:

N/A

#### Group 1 Codes: (450 Codes)

| CODE    | DESCRIPTION   |
|---------|---|
| E87.21  | Acute metabolic acidosis  |
| E87.22  | Chronic metabolic acidosis                                      |
| E87.29  | Other acidosis  |
| F10.11  | Alcohol abuse, in remission                                     |
| F10.130 | Alcohol abuse with withdrawal, uncomplicated                    |
| F10.131 | Alcohol abuse with withdrawal delirium                          |
| F10.132 | Alcohol abuse with withdrawal with perceptual disturbance       |
| F10.20  | Alcohol dependence, uncomplicated                               |
| F11.11  | Opioid abuse, in remission                                      |
| F11.13  | Opioid abuse with withdrawal                                    |
| F11.20  | Opioid dependence, uncomplicated                                |
| F11.21  | Opioid dependence, in remission                                 |
| F11.220 | Opioid dependence with intoxication, uncomplicated              |
| F11.221 | Opioid dependence with intoxication delirium                    |
| F11.222 | Opioid dependence with intoxication with perceptual disturbance |
| F11.23  | Opioid dependence with withdrawal                               |

| CODE    | DESCRIPTION  |
|---------|--|
| F11.24  | Opioid dependence with opioid-induced mood disorder                                |
| F11.250 | Opioid dependence with opioid-induced psychotic disorder with delusions            |
| F11.251 | Opioid dependence with opioid-induced psychotic disorder with hallucinations       |
| F11.281 | Opioid dependence with opioid-induced sexual dysfunction                           |
| F11.282 | Opioid dependence with opioid-induced sleep disorder                               |
| F11.288 | Opioid dependence with other opioid-induced disorder                               |
| F12.11  | Cannabis abuse, in remission   |
| F12.13  | Cannabis abuse with withdrawal   |
| F12.20  | Cannabis dependence, uncomplicated   |
| F12.23  | Cannabis dependence with withdrawal  |
| F12.93  | Cannabis use, unspecified with withdrawal  |
| F13.11  | Sedative, hypnotic or anxiolytic abuse, in remission                               |
| F13.130 | Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated              |
| F13.131 | Sedative, hypnotic or anxiolytic abuse with withdrawal delirium                    |
| F13.132 | Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance |
| F14.11  | Cocaine abuse, in remission  |
| F14.13  | Cocaine abuse, unspecified with withdrawal   |
| F14.93  | Cocaine use, unspecified with withdrawal   |
| F15.11  | Other stimulant abuse, in remission  |
| F15.13  | Other stimulant abuse with withdrawal  |
| F15.20  | Other stimulant dependence, uncomplicated  |
| F16.11  | Hallucinogen abuse, in remission   |
| F18.10  | Inhalant abuse, uncomplicated  |
| F18.11  | Inhalant abuse, in remission   |
| F18.120 | Inhalant abuse with intoxication, uncomplicated                                    |
| F18.90  | Inhalant use, unspecified, uncomplicated   |
| F19.10  | Other psychoactive substance abuse, uncomplicated                                  |
| F19.11  | Other psychoactive substance abuse, in remission                                   |
| F19.130 | Other psychoactive substance abuse with withdrawal, uncomplicated                  |
| F19.131 | Other psychoactive substance abuse with withdrawal delirium                        |
| F19.132 | Other psychoactive substance abuse with withdrawal with perceptual disturbance     |
| F19.14  | Other psychoactive substance abuse with psychoactive substance-induced mood        |

| CODE    | DESCRIPTION  |
|---------|--|
|         | disorder   |
| F19.20  | Other psychoactive substance dependence, uncomplicated   |
| F20.0   | Paranoid schizophrenia   |
| F20.1   | Disorganized schizophrenia   |
| F20.2   | Catatonic schizophrenia  |
| F20.89  | Other schizophrenia  |
| F55.0   | Abuse of antacids  |
| F55.1   | Abuse of herbal or folk remedies   |
| F55.2   | Abuse of laxatives   |
| F55.3   | Abuse of steroids or hormones  |
| F55.4   | Abuse of vitamins  |
| F55.8   | Abuse of other non-psychoactive substances   |
| G40.301 | Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticus    |
| G40.309 | Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status epilepticus |
| G40.311 | Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticus        |
| G40.319 | Generalized idiopathic epilepsy and epileptic syndromes, intractable, without status epilepticus     |
| G40.401 | Other generalized epilepsy and epileptic syndromes, not intractable, with status epilepticus         |
| G40.409 | Other generalized epilepsy and epileptic syndromes, not intractable, without status epilepticus      |
| G40.411 | Other generalized epilepsy and epileptic syndromes, intractable, with status epilepticus             |
| G40.419 | Other generalized epilepsy and epileptic syndromes, intractable, without status epilepticus          |
| G40.42  | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder   |
| G89.29  | Other chronic pain   |
| G89.4   | Chronic pain syndrome  |
| I44.0   | Atrioventricular block, first degree   |
| I44.1   | Atrioventricular block, second degree  |
| I44.30  | Unspecified atrioventricular block   |

| <b>CODE</b> | <b>DESCRIPTION</b>  |
|-------------|---|
| I45.81      | Long QT syndrome  |
| I47.0       | Re-entry ventricular arrhythmia   |
| I47.1       | Supraventricular tachycardia  |
| I47.20      | Ventricular tachycardia, unspecified  |
| I47.21      | Torsades de pointes   |
| I47.29      | Other ventricular tachycardia   |
| I49.2       | Junctional premature depolarization   |
| M25.511     | Pain in right shoulder  |
| M25.512     | Pain in left shoulder   |
| M25.59      | Pain in other specified joint   |
| M47.21      | Other spondylosis with radiculopathy, occipito-atlanto-axial region               |
| M47.22      | Other spondylosis with radiculopathy, cervical region                             |
| M47.23      | Other spondylosis with radiculopathy, cervicothoracic region                      |
| M47.26      | Other spondylosis with radiculopathy, lumbar region                               |
| M47.27      | Other spondylosis with radiculopathy, lumbosacral region                          |
| M47.28      | Other spondylosis with radiculopathy, sacral and sacrococcygeal region            |
| M47.811     | Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region    |
| M47.812     | Spondylosis without myelopathy or radiculopathy, cervical region                  |
| M47.813     | Spondylosis without myelopathy or radiculopathy, cervicothoracic region           |
| M47.816     | Spondylosis without myelopathy or radiculopathy, lumbar region                    |
| M47.817     | Spondylosis without myelopathy or radiculopathy, lumbosacral region               |
| M47.818     | Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region |
| M47.891     | Other spondylosis, occipito-atlanto-axial region                                  |
| M47.892     | Other spondylosis, cervical region  |
| M47.893     | Other spondylosis, cervicothoracic region   |
| M47.896     | Other spondylosis, lumbar region  |
| M47.897     | Other spondylosis, lumbosacral region   |
| M47.898     | Other spondylosis, sacral and sacrococcygeal region                               |
| <b>CODE</b> | <b>DESCRIPTION</b>  |
| M51.14      | Intervertebral disc disorders with radiculopathy, thoracic region                 |
| M51.15      | Intervertebral disc disorders with radiculopathy, thoracolumbar region            |
| M51.16      | Intervertebral disc disorders with radiculopathy, lumbar region                   |

| CODE    | DESCRIPTION  |
|---------|--|
| M51.17  | Intervertebral disc disorders with radiculopathy, lumbosacral region |
| M51.36  | Other intervertebral disc degeneration, lumbar region                |
| M51.37  | Other intervertebral disc degeneration, lumbosacral region           |
| M54.10  | Radiculopathy, site unspecified                                      |
| M54.12  | Radiculopathy, cervical region                                       |
| M54.14  | Radiculopathy, thoracic region                                       |
| M54.15  | Radiculopathy, thoracolumbar region                                  |
| M54.16  | Radiculopathy, lumbar region   |
| M54.17  | Radiculopathy, lumbosacral region                                    |
| M54.18  | Radiculopathy, sacral and sacrococcygeal region                      |
| M54.2   | Cervicalgia  |
| M54.50  | Low back pain, unspecified   |
| M54.51  | Vertebrogenic low back pain  |
| M54.59  | Other low back pain  |
| M60.811 | Other myositis, right shoulder                                       |
| M60.812 | Other myositis, left shoulder  |
| M60.821 | Other myositis, right upper arm                                      |
| M60.822 | Other myositis, left upper arm                                       |
| M60.831 | Other myositis, right forearm  |
| M60.832 | Other myositis, left forearm   |
| M60.841 | Other myositis, right hand   |
| M60.842 | Other myositis, left hand  |
| M60.851 | Other myositis, right thigh  |
| M60.852 | Other myositis, left thigh   |
| M60.861 | Other myositis, right lower leg                                      |
| M60.862 | Other myositis, left lower leg                                       |
| M60.871 | Other myositis, right ankle and foot                                 |
| M60.872 | Other myositis, left ankle and foot                                  |
| M60.88  | Other myositis, other site   |
| M60.89  | Other myositis, multiple sites                                       |
| M79.2   | Neuralgia and neuritis, unspecified                                  |
| M79.7   | Fibromyalgia   |

| CODE     | DESCRIPTION   |
|----------|---|
| R40.0    | Somnolence  |
| R40.1    | Stupor  |
| R40.2110 | Coma scale, eyes open, never, unspecified time  |
| R40.2111 | Coma scale, eyes open, never, in the field [EMT or ambulance]                                       |
| R40.2112 | Coma scale, eyes open, never, at arrival to emergency department                                    |
| R40.2113 | Coma scale, eyes open, never, at hospital admission   |
| R40.2114 | Coma scale, eyes open, never, 24 hours or more after hospital admission                             |
| R40.2120 | Coma scale, eyes open, to pain, unspecified time  |
| R40.2121 | Coma scale, eyes open, to pain, in the field [EMT or ambulance]                                     |
| R40.2122 | Coma scale, eyes open, to pain, at arrival to emergency department                                  |
| R40.2123 | Coma scale, eyes open, to pain, at hospital admission   |
| R40.2124 | Coma scale, eyes open, to pain, 24 hours or more after hospital admission                           |
| R40.2210 | Coma scale, best verbal response, none, unspecified time  |
| R40.2211 | Coma scale, best verbal response, none, in the field [EMT or ambulance]                             |
| R40.2212 | Coma scale, best verbal response, none, at arrival to emergency department                          |
| R40.2213 | Coma scale, best verbal response, none, at hospital admission                                       |
| R40.2214 | Coma scale, best verbal response, none, 24 hours or more after hospital admission                   |
| R40.2220 | Coma scale, best verbal response, incomprehensible words, unspecified time                          |
| R40.2221 | Coma scale, best verbal response, incomprehensible words, in the field [EMT or ambulance]           |
| R40.2222 | Coma scale, best verbal response, incomprehensible words, at arrival to emergency department        |
| R40.2223 | Coma scale, best verbal response, incomprehensible words, at hospital admission                     |
| R40.2224 | Coma scale, best verbal response, incomprehensible words, 24 hours or more after hospital admission |
| R40.2310 | Coma scale, best motor response, none, unspecified time   |
| R40.2311 | Coma scale, best motor response, none, in the field [EMT or ambulance]                              |
| R40.2312 | Coma scale, best motor response, none, at arrival to emergency department                           |
| R40.2313 | Coma scale, best motor response, none, at hospital admission  |
| R40.2314 | Coma scale, best motor response, none, 24 hours or more after hospital admission                    |
| R40.2320 | Coma scale, best motor response, extension, unspecified time  |
| R40.2321 | Coma scale, best motor response, extension, in the field [EMT or ambulance]                         |
| R40.2322 | Coma scale, best motor response, extension, at arrival to emergency department                      |

| CODE     | DESCRIPTION  |
|----------|--|
| R40.2323 | Coma scale, best motor response, extension, at hospital admission                              |
| R40.2324 | Coma scale, best motor response, extension, 24 hours or more after hospital admission          |
| R40.2340 | Coma scale, best motor response, flexion withdrawal, unspecified time                          |
| R40.2341 | Coma scale, best motor response, flexion withdrawal, in the field [EMT or ambulance]           |
| R40.2342 | Coma scale, best motor response, flexion withdrawal, at arrival to emergency department        |
| R40.2343 | Coma scale, best motor response, flexion withdrawal, at hospital admission                     |
| R40.2344 | Coma scale, best motor response, flexion withdrawal, 24 hours or more after hospital admission |
| R41.82   | Altered mental status, unspecified   |
| R44.0    | Auditory hallucinations  |
| R44.2    | Other hallucinations   |
| R44.3    | Hallucinations, unspecified  |
| R45.850  | Homicidal ideations  |
| R45.851  | Suicidal ideations   |
| R45.88   | Nonsuicidal self-harm  |
| R56.9    | Unspecified convulsions  |
| T39.011A | Poisoning by aspirin, accidental (unintentional), initial encounter                            |
| T39.012A | Poisoning by aspirin, intentional self-harm, initial encounter                                 |
| T39.013A | Poisoning by aspirin, assault, initial encounter   |
| T39.014A | Poisoning by aspirin, undetermined, initial encounter  |
| T39.091A | Poisoning by salicylates, accidental (unintentional), initial encounter                        |
| T39.092A | Poisoning by salicylates, intentional self-harm, initial encounter                             |
| T39.093A | Poisoning by salicylates, assault, initial encounter   |
| T39.094A | Poisoning by salicylates, undetermined, initial encounter                                      |
| T39.1X1A | Poisoning by 4-Aminophenol derivatives, accidental (unintentional), initial encounter          |
| T39.1X2A | Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter               |
| T39.1X3A | Poisoning by 4-Aminophenol derivatives, assault, initial encounter                             |
| T39.1X4A | Poisoning by 4-Aminophenol derivatives, undetermined, initial encounter                        |
| T39.2X1A | Poisoning by pyrazolone derivatives, accidental (unintentional), initial encounter             |
| T39.2X2A | Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter                  |

| <b>CODE</b> | <b>DESCRIPTION</b>   |
|-------------|--|
| T39.2X3A    | Poisoning by pyrazolone derivatives, assault, initial encounter  |
| T39.2X4A    | Poisoning by pyrazolone derivatives, undetermined, initial encounter   |
| T39.311A    | Poisoning by propionic acid derivatives, accidental (unintentional), initial encounter                         |
| T39.312A    | Poisoning by propionic acid derivatives, intentional self-harm, initial encounter                              |
| T39.313A    | Poisoning by propionic acid derivatives, assault, initial encounter  |
| T39.314A    | Poisoning by propionic acid derivatives, undetermined, initial encounter                                       |
| <b>CODE</b> | <b>DESCRIPTION</b>   |
| T39.391A    | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], accidental (unintentional), initial encounter |
| T39.392A    | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter      |
| T39.393A    | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, initial encounter                    |
| T39.394A    | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], undetermined, initial encounter               |
| T40.0X1A    | Poisoning by opium, accidental (unintentional), initial encounter  |
| T40.0X2A    | Poisoning by opium, intentional self-harm, initial encounter   |
| T40.0X3A    | Poisoning by opium, assault, initial encounter   |
| T40.0X4A    | Poisoning by opium, undetermined, initial encounter  |
| T40.1X1A    | Poisoning by heroin, accidental (unintentional), initial encounter   |
| T40.1X2A    | Poisoning by heroin, intentional self-harm, initial encounter  |
| T40.1X3A    | Poisoning by heroin, assault, initial encounter  |
| T40.1X4A    | Poisoning by heroin, undetermined, initial encounter   |
| T40.2X1A    | Poisoning by other opioids, accidental (unintentional), initial encounter                                      |
| T40.2X2A    | Poisoning by other opioids, intentional self-harm, initial encounter   |
| T40.2X3A    | Poisoning by other opioids, assault, initial encounter   |
| T40.2X4A    | Poisoning by other opioids, undetermined, initial encounter  |
| T40.3X1A    | Poisoning by methadone, accidental (unintentional), initial encounter  |
| T40.3X2A    | Poisoning by methadone, intentional self-harm, initial encounter   |
| T40.3X3A    | Poisoning by methadone, assault, initial encounter   |
| T40.3X4A    | Poisoning by methadone, undetermined, initial encounter  |
| T40.411A    | Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter                       |

| CODE     | DESCRIPTION   |
|----------|---|
| T40.411D | Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), subsequent encounter |
| T40.411S | Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), sequela              |
| T40.412A | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter         |
| T40.412D | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, subsequent encounter      |
| T40.412S | Poisoning by fentanyl or fentanyl analogs, intentional self-harm, sequela                   |
| T40.413A | Poisoning by fentanyl or fentanyl analogs, assault, initial encounter                       |
| T40.413D | Poisoning by fentanyl or fentanyl analogs, assault, subsequent encounter                    |
| T40.413S | Poisoning by fentanyl or fentanyl analogs, assault, sequela                                 |
| T40.414A | Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter                  |
| T40.414D | Poisoning by fentanyl or fentanyl analogs, undetermined, subsequent encounter               |
| T40.414S | Poisoning by fentanyl or fentanyl analogs, undetermined, sequela                            |
| T40.421A | Poisoning by tramadol, accidental (unintentional), initial encounter                        |
| T40.421D | Poisoning by tramadol, accidental (unintentional), subsequent encounter                     |
| T40.421S | Poisoning by tramadol, accidental (unintentional), sequela                                  |
| T40.422A | Poisoning by tramadol, intentional self-harm, initial encounter                             |
| T40.422D | Poisoning by tramadol, intentional self-harm, subsequent encounter                          |
| T40.422S | Poisoning by tramadol, intentional self-harm, sequela                                       |
| T40.423A | Poisoning by tramadol, assault, initial encounter   |
| T40.423D | Poisoning by tramadol, assault, subsequent encounter  |
| T40.423S | Poisoning by tramadol, assault, sequela   |
| T40.424A | Poisoning by tramadol, undetermined, initial encounter                                      |
| T40.424D | Poisoning by tramadol, undetermined, subsequent encounter                                   |
| T40.424S | Poisoning by tramadol, undetermined, sequela  |
| T40.491A | Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter       |
| T40.491D | Poisoning by other synthetic narcotics, accidental (unintentional), subsequent encounter    |
| T40.491S | Poisoning by other synthetic narcotics, accidental (unintentional), sequela                 |
| T40.492A | Poisoning by other synthetic narcotics, intentional self-harm, initial encounter            |
| T40.492D | Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter         |
| T40.492S | Poisoning by other synthetic narcotics, intentional self-harm, sequela                      |
| T40.493A | Poisoning by other synthetic narcotics, assault, initial encounter                          |

| CODE     | DESCRIPTION   |
|----------|---|
| T40.493D | Poisoning by other synthetic narcotics, assault, subsequent encounter                 |
| T40.493S | Poisoning by other synthetic narcotics, assault, sequela                              |
| T40.494A | Poisoning by other synthetic narcotics, undetermined, initial encounter               |
| T40.494D | Poisoning by other synthetic narcotics, undetermined, subsequent encounter            |
| T40.494S | Poisoning by other synthetic narcotics, undetermined, sequela                         |
| T40.601A | Poisoning by unspecified narcotics, accidental (unintentional), initial encounter     |
| T40.602A | Poisoning by unspecified narcotics, intentional self-harm, initial encounter          |
| T40.603A | Poisoning by unspecified narcotics, assault, initial encounter                        |
| T40.604A | Poisoning by unspecified narcotics, undetermined, initial encounter                   |
| T40.691A | Poisoning by other narcotics, accidental (unintentional), initial encounter           |
| T40.692A | Poisoning by other narcotics, intentional self-harm, initial encounter                |
| T40.693A | Poisoning by other narcotics, assault, initial encounter                              |
| T40.694A | Poisoning by other narcotics, undetermined, initial encounter                         |
| T40.711A | Poisoning by cannabis, accidental (unintentional), initial encounter                  |
| T40.711D | Poisoning by cannabis, accidental (unintentional), subsequent encounter               |
| T40.711S | Poisoning by cannabis, accidental (unintentional), sequela                            |
| T40.712A | Poisoning by cannabis, intentional self-harm, initial encounter                       |
| T40.712D | Poisoning by cannabis, intentional self-harm, subsequent encounter                    |
| T40.712S | Poisoning by cannabis, intentional self-harm, sequela                                 |
| T40.713A | Poisoning by cannabis, assault, initial encounter                                     |
| T40.713D | Poisoning by cannabis, assault, subsequent encounter                                  |
| T40.713S | Poisoning by cannabis, assault, sequela   |
| T40.714A | Poisoning by cannabis, undetermined, initial encounter                                |
| T40.714D | Poisoning by cannabis, undetermined, subsequent encounter                             |
| T40.714S | Poisoning by cannabis, undetermined, sequela  |
| T40.721A | Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter    |
| T40.721D | Poisoning by synthetic cannabinoids, accidental (unintentional), subsequent encounter |
| T40.721S | Poisoning by synthetic cannabinoids, accidental (unintentional), sequela              |
| T40.722A | Poisoning by synthetic cannabinoids, intentional self-harm, initial encounter         |
| T40.722D | Poisoning by synthetic cannabinoids, intentional self-harm, subsequent encounter      |
| T40.722S | Poisoning by synthetic cannabinoids, intentional self-harm, sequela                   |

| <b>CODE</b> | <b>DESCRIPTION</b>   |
|-------------|--|
| T40.723A    | Poisoning by synthetic cannabinoids, assault, initial encounter  |
| T40.723D    | Poisoning by synthetic cannabinoids, assault, subsequent encounter                                       |
| T40.723S    | Poisoning by synthetic cannabinoids, assault, sequela  |
| T40.724A    | Poisoning by synthetic cannabinoids, undetermined, initial encounter                                     |
| T40.724D    | Poisoning by synthetic cannabinoids, undetermined, subsequent encounter                                  |
| T40.724S    | Poisoning by synthetic cannabinoids, undetermined, sequela   |
| T40.8X1A    | Poisoning by lysergide [LSD], accidental (unintentional), initial encounter                              |
| T40.8X2A    | Poisoning by lysergide [LSD], intentional self-harm, initial encounter                                   |
| T40.8X3A    | Poisoning by lysergide [LSD], assault, initial encounter   |
| T40.8X4A    | Poisoning by lysergide [LSD], undetermined, initial encounter  |
| T40.901A    | Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter |
| T40.902A    | Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter      |
| T40.903A    | Poisoning by unspecified psychodysleptics [hallucinogens], assault, initial encounter                    |
| T40.904A    | Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, initial encounter               |
| T40.991A    | Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter       |
| T40.992A    | Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter            |
| T40.993A    | Poisoning by other psychodysleptics [hallucinogens], assault, initial encounter                          |
| T40.994A    | Poisoning by other psychodysleptics [hallucinogens], undetermined, initial encounter                     |
| <b>CODE</b> | <b>DESCRIPTION</b>   |
| T42.0X1A    | Poisoning by hydantoin derivatives, accidental (unintentional), initial encounter                        |
| T42.0X2A    | Poisoning by hydantoin derivatives, intentional self-harm, initial encounter                             |
| T42.0X3A    | Poisoning by hydantoin derivatives, assault, initial encounter   |
| T42.0X4A    | Poisoning by hydantoin derivatives, undetermined, initial encounter                                      |
| T42.3X1A    | Poisoning by barbiturates, accidental (unintentional), initial encounter                                 |
| T42.3X2A    | Poisoning by barbiturates, intentional self-harm, initial encounter                                      |
| T42.3X3A    | Poisoning by barbiturates, assault, initial encounter  |
| T42.3X4A    | Poisoning by barbiturates, undetermined, initial encounter   |
| T42.4X1A    | Poisoning by benzodiazepines, accidental (unintentional), initial encounter                              |

| CODE     | DESCRIPTION   |
|----------|---|
| T42.4X2A | Poisoning by benzodiazepines, intentional self-harm, initial encounter  |
| T42.4X3A | Poisoning by benzodiazepines, assault, initial encounter  |
| T42.4X4A | Poisoning by benzodiazepines, undetermined, initial encounter   |
| T42.6X1A | Poisoning by other antiepileptic and sedative-hypnotic drugs, accidental (unintentional), initial encounter       |
| T42.6X2A | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter            |
| T42.6X3A | Poisoning by other antiepileptic and sedative-hypnotic drugs, assault, initial encounter                          |
| T42.6X4A | Poisoning by other antiepileptic and sedative-hypnotic drugs, undetermined, initial encounter                     |
| T42.71XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, accidental (unintentional), initial encounter |
| T42.72XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter      |
| T42.73XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, assault, initial encounter                    |
| T42.74XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, undetermined, initial encounter               |
| T43.011A | Poisoning by tricyclic antidepressants, accidental (unintentional), initial encounter                             |
| T43.012A | Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter                                  |
| T43.013A | Poisoning by tricyclic antidepressants, assault, initial encounter  |
| T43.014A | Poisoning by tricyclic antidepressants, undetermined, initial encounter   |
| T43.021A | Poisoning by tetracyclic antidepressants, accidental (unintentional), initial encounter                           |
| T43.022A | Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter                                |
| T43.023A | Poisoning by tetracyclic antidepressants, assault, initial encounter  |
| T43.024A | Poisoning by tetracyclic antidepressants, undetermined, initial encounter   |
| T43.1X1A | Poisoning by monoamine-oxidase-inhibitor antidepressants, accidental (unintentional), initial encounter           |
| T43.1X2A | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter                |
| T43.1X3A | Poisoning by monoamine-oxidase-inhibitor antidepressants, assault, initial encounter                              |
| T43.1X4A | Poisoning by monoamine-oxidase-inhibitor antidepressants, undetermined, initial encounter                         |

| CODE     | DESCRIPTION  |
|----------|--|
| T43.201A | Poisoning by unspecified antidepressants, accidental (unintentional), initial encounter                                |
| T43.202A | Poisoning by unspecified antidepressants, intentional self-harm, initial encounter                                     |
| T43.203A | Poisoning by unspecified antidepressants, assault, initial encounter   |
| T43.204A | Poisoning by unspecified antidepressants, undetermined, initial encounter  |
| T43.211A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, accidental (unintentional), initial encounter |
| T43.212A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter      |
| T43.213A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, assault, initial encounter                    |
| T43.214A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, undetermined, initial encounter               |
| T43.221A | Poisoning by selective serotonin reuptake inhibitors, accidental (unintentional), initial encounter                    |
| T43.222A | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter                         |
| T43.223A | Poisoning by selective serotonin reuptake inhibitors, assault, initial encounter                                       |
| T43.224A | Poisoning by selective serotonin reuptake inhibitors, undetermined, initial encounter                                  |
| T43.291A | Poisoning by other antidepressants, accidental (unintentional), initial encounter                                      |
| T43.292A | Poisoning by other antidepressants, intentional self-harm, initial encounter   |
| T43.293A | Poisoning by other antidepressants, assault, initial encounter   |
| T43.294A | Poisoning by other antidepressants, undetermined, initial encounter  |
| T43.3X1A | Poisoning by phenothiazine antipsychotics and neuroleptics, accidental (unintentional), initial encounter              |
| T43.3X2A | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter                   |
| T43.3X3A | Poisoning by phenothiazine antipsychotics and neuroleptics, assault, initial encounter                                 |
| T43.3X4A | Poisoning by phenothiazine antipsychotics and neuroleptics, undetermined, initial encounter                            |
| T43.4X1A | Poisoning by butyrophenone and thiothixene neuroleptics, accidental (unintentional), initial encounter                 |
| T43.4X2A | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter                      |

| CODE     | DESCRIPTION   |
|----------|---|
| T43.4X3A | Poisoning by butyrophenone and thiothixene neuroleptics, assault, initial encounter                     |
| T43.4X4A | Poisoning by butyrophenone and thiothixene neuroleptics, undetermined, initial encounter                |
| T43.501A | Poisoning by unspecified antipsychotics and neuroleptics, accidental (unintentional), initial encounter |
| T43.502A | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter      |
| T43.503A | Poisoning by unspecified antipsychotics and neuroleptics, assault, initial encounter                    |
| T43.504A | Poisoning by unspecified antipsychotics and neuroleptics, undetermined, initial encounter               |
| T43.591A | Poisoning by other antipsychotics and neuroleptics, accidental (unintentional), initial encounter       |
| T43.592A | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter            |
| T43.593A | Poisoning by other antipsychotics and neuroleptics, assault, initial encounter                          |
| T43.594A | Poisoning by other antipsychotics and neuroleptics, undetermined, initial encounter                     |
| T43.601A | Poisoning by unspecified psychostimulants, accidental (unintentional), initial encounter                |
| T43.602A | Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter                     |
| T43.603A | Poisoning by unspecified psychostimulants, assault, initial encounter                                   |
| T43.604A | Poisoning by unspecified psychostimulants, undetermined, initial encounter                              |
| T43.611A | Poisoning by caffeine, accidental (unintentional), initial encounter                                    |
| T43.612A | Poisoning by caffeine, intentional self-harm, initial encounter   |
| T43.613A | Poisoning by caffeine, assault, initial encounter   |
| T43.614A | Poisoning by caffeine, undetermined, initial encounter  |
| T43.621A | Poisoning by amphetamines, accidental (unintentional), initial encounter                                |
| T43.622A | Poisoning by amphetamines, intentional self-harm, initial encounter                                     |
| T43.623A | Poisoning by amphetamines, assault, initial encounter   |
| T43.624A | Poisoning by amphetamines, undetermined, initial encounter  |
| T43.631A | Poisoning by methylphenidate, accidental (unintentional), initial encounter                             |
| T43.632A | Poisoning by methylphenidate, intentional self-harm, initial encounter                                  |
| T43.633A | Poisoning by methylphenidate, assault, initial encounter  |
| T43.634A | Poisoning by methylphenidate, undetermined, initial encounter   |
| T43.641A | Poisoning by ecstasy, accidental (unintentional), initial encounter                                     |

| <b>CODE</b> | <b>DESCRIPTION</b>   |
|-------------|--|
| T43.641D    | Poisoning by ecstasy, accidental (unintentional), subsequent encounter             |
| T43.641S    | Poisoning by ecstasy, accidental (unintentional), sequela                          |
| T43.642A    | Poisoning by ecstasy, intentional self-harm, initial encounter                     |
| T43.642D    | Poisoning by ecstasy, intentional self-harm, subsequent encounter                  |
| T43.642S    | Poisoning by ecstasy, intentional self-harm, sequela                               |
| T43.643A    | Poisoning by ecstasy, assault, initial encounter                                   |
| T43.643D    | Poisoning by ecstasy, assault, subsequent encounter                                |
| T43.643S    | Poisoning by ecstasy, assault, sequela   |
| T43.644A    | Poisoning by ecstasy, undetermined, initial encounter                              |
| T43.644D    | Poisoning by ecstasy, undetermined, subsequent encounter                           |
| T43.644S    | Poisoning by ecstasy, undetermined, sequela  |
| T43.651A    | Poisoning by methamphetamines accidental (unintentional), initial encounter        |
| T43.651D    | Poisoning by methamphetamines accidental (unintentional), subsequent encounter     |
| T43.651S    | Poisoning by methamphetamines accidental (unintentional), sequela                  |
| T43.652A    | Poisoning by methamphetamines intentional self-harm, initial encounter             |
| T43.652D    | Poisoning by methamphetamines intentional self-harm, subsequent encounter          |
| T43.652S    | Poisoning by methamphetamines intentional self-harm, sequela                       |
| T43.653A    | Poisoning by methamphetamines, assault, initial encounter                          |
| T43.653D    | Poisoning by methamphetamines, assault, subsequent encounter                       |
|             |  |
| <b>CODE</b> | <b>DESCRIPTION</b>   |
| T43.653S    | Poisoning by methamphetamines, assault, sequela                                    |
| T43.654A    | Poisoning by methamphetamines, undetermined, initial encounter                     |
| T43.654D    | Poisoning by methamphetamines, undetermined, subsequent encounter                  |
| T43.654S    | Poisoning by methamphetamines, undetermined, sequela                               |
| T43.655A    | Adverse effect of methamphetamines, initial encounter                              |
| T43.655D    | Adverse effect of methamphetamines, subsequent encounter                           |
| T43.655S    | Adverse effect of methamphetamines, sequela  |
| T43.656A    | Underdosing of methamphetamines, initial encounter                                 |
| T43.656D    | Underdosing of methamphetamines, subsequent encounter                              |
| T43.656S    | Underdosing of methamphetamines, sequela   |
| T43.691A    | Poisoning by other psychostimulants, accidental (unintentional), initial encounter |
| T43.692A    | Poisoning by other psychostimulants, intentional self-harm, initial encounter      |

| CODE     | DESCRIPTION  |
|----------|--|
| T43.693A | Poisoning by other psychostimulants, assault, initial encounter  |
| T43.694A | Poisoning by other psychostimulants, undetermined, initial encounter   |
| T43.8X1A | Poisoning by other psychotropic drugs, accidental (unintentional), initial encounter                                 |
| T43.8X2A | Poisoning by other psychotropic drugs, intentional self-harm, initial encounter                                      |
| T43.8X3A | Poisoning by other psychotropic drugs, assault, initial encounter  |
| T43.8X4A | Poisoning by other psychotropic drugs, undetermined, initial encounter   |
| T43.91XA | Poisoning by unspecified psychotropic drug, accidental (unintentional), initial encounter                            |
| T43.92XA | Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter                                 |
| T43.93XA | Poisoning by unspecified psychotropic drug, assault, initial encounter   |
| T43.94XA | Poisoning by unspecified psychotropic drug, undetermined, initial encounter  |
| T45.0X1A | Poisoning by antiallergic and antiemetic drugs, accidental (unintentional), initial encounter                        |
| T45.0X2A | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter                             |
| T45.0X3A | Poisoning by antiallergic and antiemetic drugs, assault, initial encounter   |
| T45.0X4A | Poisoning by antiallergic and antiemetic drugs, undetermined, initial encounter                                      |
| T46.0X1A | Poisoning by cardiac-stimulant glycosides and drugs of similar action, accidental (unintentional), initial encounter |
| T46.0X2A | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter      |
| T46.0X3A | Poisoning by cardiac-stimulant glycosides and drugs of similar action, assault, initial encounter                    |
| T46.0X4A | Poisoning by cardiac-stimulant glycosides and drugs of similar action, undetermined, initial encounter               |
| T50.901A | Poisoning by unspecified drugs, medicaments and biological substances, accidental (unintentional), initial encounter |
| T50.902A | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter      |
| T50.903A | Poisoning by unspecified drugs, medicaments and biological substances, assault, initial encounter                    |
| T50.904A | Poisoning by unspecified drugs, medicaments and biological substances, undetermined, initial encounter               |
| Z03.821  | Encounter for observation for suspected ingested foreign body ruled out  |
| Z03.822  | Encounter for observation for suspected aspirated (inhaled) foreign body ruled out                                   |

| CODE    | DESCRIPTION  |
|---------|--|
| Z03.823 | Encounter for observation for suspected inserted (injected) foreign body ruled out         |
| Z03.89  | Encounter for observation for other suspected diseases and conditions ruled out            |
| Z51.81  | Encounter for therapeutic drug level monitoring  |
| Z79.3   | Long term (current) use of hormonal contraceptives   |
| Z79.891 | Long term (current) use of opiate analgesic  |
| Z79.899 | Other long term (current) drug therapy   |
| Z91.141 | Patient's other noncompliance with medication regimen due to financial hardship            |
| Z91.148 | Patient's other noncompliance with medication regimen for other reason                     |
| Z91.151 | Patient's noncompliance with renal dialysis due to financial hardship                      |
| Z91.158 | Patient's noncompliance with renal dialysis for other reason                               |
| Z91.190 | Patient's noncompliance with other medical treatment and regimen due to financial hardship |
| Z91.198 | Patient's noncompliance with other medical treatment and regimen for other reason          |
| Z91.199 | Patient's noncompliance with other medical treatment and regimen due to unspecified reason |

### ICD-10-CM Codes that DO NOT Support Medical Necessity

#### Group 1 Paragraph:

N/A

#### Group 1 Codes:

N/A

### ICD-10-PCS Codes

#### Group 1 Paragraph:

N/A

#### Group 1 Codes:

N/A

### Additional ICD-10 Information

N/A

### Bill Type Codes

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the article should be assumed to apply equally to all claims.

| CODE | DESCRIPTION    |
|------|----------------|
| 999x | Not Applicable |

### Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.

N/A

### Other Coding Information

#### Group 1 Paragraph:

N/A

#### Group 1 Codes:

N/A

## Revision History Information

| REVISION HISTORY DATE | REVISION HISTORY NUMBER | REVISION HISTORY EXPLANATION  |
|-----------------------|-------------------------|---|
| 07/01/2023            | R18                     | Under CPT/HCPCS Group 1 Codes, removed codes 0143U, 0144U, 0145U, 0146U, 0147U, 0148U, 0149U and 0150U per Q3 2023 CPT/HCPCS Updates. |
| 04/01/2023            | R17                     | Under Group 1: ICD-10 Codes That Support Medical Necessity, added Z91.141, Z91.148, Z91.151, Z91.158 effective 04/01/2023.            |
| 10/01/2022            | R16                     | Under Group 1: ICD-10 Codes That Support Medical Necessity, added Z91.198 and Z91.199 effective 10/01/2022.                           |

| REVISION HISTORY DATE | REVISION HISTORY NUMBER | REVISION HISTORY EXPLANATION   |
|-----------------------|-------------------------|--|
| 10/01/2022            | R15                     | Under Group 1: ICD-10 Codes That Support Medical Necessity, added F11.21, F12.20, F15.20, F19.10, F19.14 effective 01/01/2022.   |
| 10/01/2022            | R14                     | Effective 10/01/2022 - Annual ICD-10 Updates:<br>The following ICD-10 codes were deleted from Group 1:<br>E87.2, I47.2, Z91.19<br>The following ICD-10 codes were added to Group 1:<br>E87.21, E87.22, E87.29, I47.20, I47.21, I47.29, T43.651A, T43.651D, T43.651S, T43.652A, T43.652D, T43.652S, T43.653A, T43.653D, T43.653S, T43.654A, T43.654D, T43.654S, T43.655A, T43.655D, T43.655S, T43.656A, T43.656D, T43.656S, Z91.19                                      |
| 10/01/2021            | R13                     | ICD-10 code M25.9 was incorrectly noted as being deleted in revision history #12. This was a typographical error. M25.9 does not apply to this billing and coding article.   |
| 10/01/2021            | R12                     | Under Group 1: ICD-10-Codes that Support Medical Necessity deleted code M25.9; added M54.50, M54.51, M54.59. This revision is effective 10/01/2021.  |
| 10/01/2021            | R11                     | Under ICD-10 Codes that Support Medical Necessity Group 1: Codes deleted M54.5, T40.7X1A, T40.7X2A, T40.7X3A, T40.7X4A and added R45.88, T40.711A, T40.711D, T40.711S, T40.712A, T40.712D, T40.712S, T40.713A, T40.713D, T40.713S, T40.714A, T40.714D, T40.714S, T40.721A, T40.721D, T40.721S, T40.722A, T40.722D, T40.722S, T40.723A, T40.723D, T40.723S, T40.724A, T40.724D, T40.724S. This revision is due to the Annual ICD-10 update and is effective on 10/1/21. |
| 01/01/2021            | R10                     | Under ICD-10 Codes that Support Medical Necessity – Group 1: Codes deleted codes F11.229, F11.259, F11.29, G40.901, G40.909, G40.911, G40.919, M25.50, M60.9 and R40.20. This revision is effective on 10/1/20.  |
| 01/01/2021            | R9                      | Under <b>CMS National Coverage Policy</b> added the regulation for CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 15, §80.1.2 - A/B MAC (B) Contacts with Independent Clinical Laboratories to this section. This revision has a retroactive effective date of 1/1/21.<br><br>Under <b>CPT/HCPCS Codes Group 1: Codes</b> added code 0227U due to the Q1 2021 CPT/HCPCS code update and has a retroactive effective date of 1/1/21.    |
| 10/01/2020            | R8                      | Under ICD-10 Codes that Support Medical Necessity – Group 1: Codes added codes F10.130, F10.131, F10.132, F11.13, F12.13, F13.130, F13.131, F13.132, F14.13, F14.93, F15.13, F19.130, F19.131, F19.132, G40.42, T40.411A, T40.411D, T40.411S, T40.412A, T40.412D, T40.412S, T40.413A, T40.413D, T40.413S, T40.414A, T40.414D, T40.414S, T40.421A, T40.421D, T40.421S, T40.422A, T40.422D, T40.422S, T40.423A,  |

| REVISION HISTORY DATE | REVISION HISTORY NUMBER | REVISION HISTORY EXPLANATION   |
|-----------------------|-------------------------|--|
|                       |                         | <p>T40.423D, T40.423S, T40.424A, T40.424D, T40.424S, T40.491A, T40.491D, T40.491S, T40.492A, T40.492D, T40.492S, T40.493A, T40.493D, T40.493S, T40.494A, T40.494D, T40.494S, Z03.821, Z03.822, Z03.823 and deleted codes T40.4X1A, T40.4X2A, T40.4X3A, and T40.4X4A. This revision is due to the Annual ICD-10 Code Update and is effective on 10/1/20.</p> <p>Under ICD-10 Codes that Support Medical Necessity – Group 1: Codes deleted codes F11.229, F11.259, F11.29, G40.901, G40.909, G40.911, G40.919, M25.50, M60.9 and R40.20. This revision is effective on 10/1/20.</p>   |
| 01/01/2020            | R7                      | <p>01/01/2020: Under <b>CPT/HCPCS Codes Group 1: Codes</b> added HCPCS codes 0143U, 0144U, 0145U, 0146U, 0147U, 0148U, 0149U, 0150U. This revision is due to the Annual CPT<sup>®</sup>/HCPCS Code Update and becomes effective on 1/1/2020.</p> <p>This article is being revised in order to adhere to CMS requirements per chapter 13, section 13.5.1 of the Program Integrity Manual.</p>   |
| 10/01/2019            | R6                      | <p>10/01/2019: This article is being revised in order to adhere to CMS requirements per chapter 13, section 13.5.1 of the Program Integrity Manual.</p> <p>Title XVIII of the Social Security Act, §1833(e) was removed from the <b>CMS National Coverage Policy</b> section of the related Lab: Controlled Substance Monitoring and Drugs of Abuse Testing L36707 LCD and placed in this article.</p>   |
| 10/01/2019            | R5                      | <p>Added the word "Testing" at the end of the title.</p> <p>In the Article Text, added the word "Testing" at the end of the sentence.</p> <p>id="frmMainForm" class="form-horizontal" action="/edit_article.aspx?which=edit" method="post"&gt;</p>   |
| 10/01/2019            | R4                      | <p>All coding located in the <b>Coding Information</b> section has been removed from the related Lab: Controlled Substance Monitoring and Drugs of Abuse Testing L36707 LCD and added to this article.</p> <p>Under <b>Article Title</b> changed the title from the related "Billing and Coding: 2018 Controlled Substance Monitoring and Drugs of Abuse Coding and Billing Guidelines" to "Billing and Coding: Lab: Controlled Substance Monitoring and Drugs of Abuse Testing". Under <b>Article Text</b> added the sentence "The information in this article contains billing, coding, or other guidelines that complement the Local Coverage Determination (LCD) for Lab: Controlled Substance Monitoring and Drugs of Abuse Testing L36707" for the first paragraph and added the last paragraph. Formatting, punctuation and typographical</p> |

| REVISION HISTORY DATE | REVISION HISTORY NUMBER | REVISION HISTORY EXPLANATION  |
|-----------------------|-------------------------|---|
|                       |                         | errors were corrected throughout the article.   |
| 01/01/2017            | R3                      | 05/15/2018: Change of year in title to 2018.  |
| 01/01/2017            | R2                      | 03/30/2017 - Under "Presumptive Urine Drug Testing (UDT) " corrected the types of presumptive UDT available per patient DOS from four to three. Under "Definitive (Qualitative or Quantitative) UDT Testing" corrected the number of UDT services per patient DOS from four to five.  |
| 01/01/2017            | R1                      | Added the reminder sentence for DOS. Changed the first sentence under Presumptive Urine Drug Testing (UDT); to read "...four types of presumptive UDT..." instead of three. Added new 2017 CPT/HCPCS codes, replaced 2016 with 2017 and replaced "encounter" with DOS.<br>Deleted G0477, G0478 and G0479 under Presumptive Urine Drug Testing topic; Added G0659, 80305, 80306 and 80307; Replaced the word "encounter" with DOS. |

## Associated Documents

### Related Local Coverage Documents

#### LCDs

[L36707 - Lab: Controlled Substance Monitoring and Drugs of Abuse Testing](#)

### Related National Coverage Documents

N/A

### Statutory Requirements URLs

N/A

### Rules and Regulations URLs

N/A

### CMS Manual Explanations URLs

N/A

### Other URLs

N/A

### Public Versions

| UPDATED ON  | EFFECTIVE DATES  | STATUS                             |
|---|------------------|------------------------------------|
| Some older versions have been archived. Please visit the MCD Archive Site to retrieve them. |                  |                                    |
| 06/22/2023  | 07/01/2023 - N/A | Currently in Effect (This Version) |

| UPDATED ON | EFFECTIVE DATES         | STATUS     |
|------------|-------------------------|------------|
| 03/21/2023 | 04/01/2023 - 06/30/2023 | Superseded |
| 12/22/2022 | 10/01/2022 - 03/31/2023 | Superseded |
| 10/25/2022 | 10/01/2022 - N/A        | Superseded |
| 09/02/2022 | 10/01/2022 - N/A        | Superseded |
| 03/29/2022 | 10/01/2021 - 09/30/2022 | Superseded |
| 01/18/2022 | 10/01/2021 - N/A        | Superseded |
| 09/02/2021 | 10/01/2021 - N/A        | Superseded |

---

## Keywords

N/A